Debottlenecking mevalonate pathway for antimalarial drug precursor amorphadiene biosynthesis in Yarrowia lipolytica

Marsafari, Monireh; Xu, Peng

Debottlenecking mevalonate pathway for antimalarial drug precursor amorphadiene biosynthesis in Yarrowia lipolytica

dc.contributor.author	Marsafari, Monireh
dc.contributor.author	Xu, Peng
dc.date.accessioned	2020-03-04T15:46:24Z
dc.date.available	2020-03-04T15:46:24Z
dc.date.issued	2020-06-10
dc.description.abstract	World Health Organization reports that half of the population in developing countries are at risk of malaria infection. Artemisinin, the most potent anti-malaria drug, is a sesquiterpene endoperoxide extracted from the plant Artemisia annua. Due to scalability and economics issues, plant extraction or chemical synthesis could not provide a sustainable route for large-scale manufacturing of artemisinin. The price of artemisinin has been fluctuating from 200$/Kg to 1100$/Kg, due to geopolitical and climate factors. Microbial fermentation was considered as a promising method to stabilize the artemisinin supply chain. Yarrowia lipolytica, is an oleaginous yeast with proven capacity to produce large quantity of lipids and oleochemicals. In this report, the lipogenic acetyl-CoA pathways and the endogenous mevalonate pathway of Y. lipolytica were harnessed for amorphadiene production. Gene overexpression indicate that HMG-CoA and acetyl-CoA supply are two limiting bottlenecks for amorphadiene production. We have identified the optimal HMG-CoA reductase and determined the optimal gene copy number for the precursor pathways. Amorphadiene production was improved further by either inhibiting fatty acids synthase or activating the fatty acid degradation pathway. With co-expression of mevalonate kinase (encoded by Erg12), a push-and-pull strategy enabled the engineered strain to produce 171.5 mg/L of amorphadiene in shake flasks. These results demonstrate that balancing carbon flux and manipulation of precursor competing pathways are key factors to improve amorphadiene biosynthesis in oleaginous yeast; and Y. lipolytica is a promising microbial host to expand nature’s biosynthetic capacity, allowing us to quickly access antimalarial drug precursors.	en_US
dc.description.sponsorship	We would like to acknowledge Bill & Melinda Gates Foundation (grant number OPP1188443) and National Science Foundation (CBET- 1805139) for financially supporting this project. We would also like to acknowledge the Department of Chemical, Biochemical and Environmental Engineering at University of Maryland Baltimore County for funding support.	en_US
dc.description.uri	https://www.sciencedirect.com/science/article/pii/S2214030119300458	en_US
dc.format.extent	7 pages	en_US
dc.genre	journal articles	en_US
dc.identifier	doi:10.13016/m2o34a-ivod
dc.identifier.citation	Monireh Marsafari, Peng Xu, Vol 10, 2020,https://doi.org/10.1016/j.mec.2019.e00121	en_US
dc.identifier.uri	https://doi.org/10.1016/j.mec.2019.e00121
dc.identifier.uri	http://hdl.handle.net/11603/17466
dc.language.iso	en_US	en_US
dc.publisher	Elsevier B.V.	en_US
dc.relation.isAvailableAt	The University of Maryland, Baltimore County (UMBC)
dc.relation.ispartof	UMBC Biological Sciences Department Collection
dc.relation.ispartof	UMBC Faculty Collection
dc.relation.ispartof	UMBC Student Collection
dc.rights	This item is likely protected under Title 17 of the U.S. Copyright Law. Unless on a Creative Commons license, for uses protected by Copyright Law, contact the copyright holder or the author.
dc.rights	Attribution 4.0 International (CC BY 4.0)	*
dc.rights.uri	https://creativecommons.org/licenses/by/4.0/	*
dc.title	Debottlenecking mevalonate pathway for antimalarial drug precursor amorphadiene biosynthesis in Yarrowia lipolytica	en_US
dc.type	Text	en_US